Virtus Biotech Clinical Trials ETF
20 hedge funds and large institutions have $12.3M invested in Virtus Biotech Clinical Trials ETF in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
21% more capital invested
Capital invested by funds: $10.2M → $12.3M (+$2.18M)
5% more funds holding
Funds holding: 19 → 20 (+1)
2.51% more ownership
Funds ownership: 32.31% → 34.82% (+2.5%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.23M |
| 2 |
QCM
Quantinno Capital Management
New York
|
+$794K |
| 3 |
APW
Aurora Private Wealth
Rockaway,
New Jersey
|
+$466K |
| 4 |
FTUS
Flow Traders U.S.
New York
|
+$425K |
| 5 |
KCP
Kera Capital Partners
San Jose,
California
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MML Investors Services
Springfield,
Massachusetts
|
-$576K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$526K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
-$487K |
| 4 |
HF
HRT Financial
New York
|
-$234K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$198K |
BBC Hedge Fund Activity: Q1 2026 in Review
20 of the 8,196 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2026, worth a combined $12.3M — up 21% from $10.2M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BBC positions and 4 closed out — a net gain of 2 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $1.23M. The largest seller was MML Investors Services, exiting entirely with an estimated $576K sold.
- 20 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2026, up from 19 in Q4 2025.
- Funds reported $12.3M of Virtus Biotech Clinical Trials ETF stock for Q1 2026, up 21% quarter-over-quarter.
- 6 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2026 and 4 closed out, a net change of +2 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2026 was Susquehanna International Group, an estimated $1.23M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2026 was MML Investors Services, an estimated $576K sold.
Based on aggregated 13F filings for Q1 2026.